1. Home
  2. ORGN vs KPTI Comparison

ORGN vs KPTI Comparison

Compare ORGN & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Origin Materials Inc.

ORGN

Origin Materials Inc.

HOLD

Current Price

$0.48

Market Cap

109.4M

Sector

Industrials

ML Signal

HOLD

Logo Karyopharm Therapeutics Inc.

KPTI

Karyopharm Therapeutics Inc.

HOLD

Current Price

$5.58

Market Cap

94.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ORGN
KPTI
Founded
2008
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
109.4M
94.6M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
ORGN
KPTI
Price
$0.48
$5.58
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$22.17
AVG Volume (30 Days)
978.9K
109.8K
Earning Date
11-13-2025
11-03-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$25,122,000.00
$142,530,000.00
Revenue This Year
$49.18
$4.87
Revenue Next Year
$144.81
$9.20
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.40
$3.51
52 Week High
$1.36
$12.97

Technical Indicators

Market Signals
Indicator
ORGN
KPTI
Relative Strength Index (RSI) 41.03 46.85
Support Level $0.41 $5.31
Resistance Level $0.49 $6.50
Average True Range (ATR) 0.04 0.41
MACD -0.00 0.00
Stochastic Oscillator 39.80 35.29

Price Performance

Historical Comparison
ORGN
KPTI

About ORGN Origin Materials Inc.

Origin Materials Inc is a carbon-negative materials company. The platform turns the carbon found in biomass into useful materials, while eliminating the need for fossil resources and capturing carbon in the process. Its products include, PET circular caps and closures, Para-xylene, carbon black, Levulinic acid among others by using materials like food and beverage packaging, clothing, textiles, plastics, car parts, carpeting, tires, adhesives, soil amendments, and fuels.

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Share on Social Networks: